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CRANIAL BASE SURGERY
The combined cranial facial approach to the paranasal 
sinuses was reported by Smith, Klopp and Williams in 
1954 [46]. Ketcham et al [47] in 1963 further refined the 
technique and called it “Combined Intracranial Facial 
Approach to the Paranasal Sinuses.” This combined ap-
proach allowed a more accurate determination of the true 
extent of disease and facilitated enbloc resection of the 
paranasal sinuses in continuity with the cribiform plate 
area of the anterior cranial fossa and the medial wall of 
the orbit. By the 1980s most head and neck surgical units 
had embraced this approach for tumors of the cranial 
base. This operation produced good oncologic results, but 
often at the expense of a relatively unpleasing cosmetic 
result due to the open facial approach. Reconstruction 
during the early days was suboptimal and resulted in 
some major problems. There were also major difficulties 
with managing postoperative cerebrospinal fluid leak 
and meningitis. 
The introduction of endoscopic technology has had a 
major positive impact on the management of tumors of 
the sinonasal tract. Benign tumors such as the inverted 
papilloma and angiofibroma are ideally suited for endo-
scopic removal. Published series have demonstrated that 
endoscopic excision of properly selected tumors are asso-
ciated with improved local tumor control and decreased 
morbidity compared with the standard open approach. 
The application of endonasal endoscopic techniques to 
the management of malignant sinonasal tumors has been 
somewhat controversial. Snyderman, et al. [48] state that 
the primary goal of oncologic surgery is complete excision 
of the neoplasm. Although different instrumentation is 
used with endoscopic surgery, the surgical strategy is 
similar to the open procedure. Enbloc resection of the 
entire tumor is not necessary, but enbloc excision of 
the area of tumor invasion is the essential part of the 
procedure. This is best exemplified by the treatment of 
olfactory neuroblastoma where a bulky tumor may have 
only a small area of attachment to the cribiform plate. It 
is frequently necessary to debulk these tumors to gain 
access to the area of invasion. 
Contrary to the usual principals in surgical oncol-
ogy of not violating the tumor, this technique violates 
the tumor but does not violate normal tissue planes 
since most of the tumor is residing in the airfilled cav-
ity. Currently there is no evidence that debulking the 
tumor increases the risk of local recurrence. There are, 
in fact, multiple examples of other neoplasms that are 
removed in a piece meal fashion without compromising 
results such as laser resection of pharyngeal and laryn-
geal squamous carcinomas and microscopic control of 
excision of skin cancers (Mohs technique). The authors 
state that even using open techniques, enbloc excision is 
not possible because of fragmentation of the specimen 
as well as proximity to vital structures. In such cases, 
the endonasal approach may actually decrease the risk 
of tumor seeding, but ultimately it is the final resection 
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margin that is important, not so much the method of 
tumor removal. 
Radiation therapy is an important adjunct to this 
approach, particularly in high grade malignancies when 
they involve critical structures, such as the brain, optic 
nerve, carotid artery or cavernous sinus when complete 
resection is not feasible. In such cases, chemoradiation 
is considered as the first therapy with surgical salvage 
for residual tumor following treatment of tumors such 
as nasopharyngeal carcinoma. 
Endoscopic debulking of tumors may also be consid-
ered for palliation of symptoms such as: pain, epistaxis, 
nasal obstruction, visual loss, and cranial neuropathies 
secondary to compression. In their series of patients, 
the authors had a very low rate of complications such 
as wound infection and central nervous system related 
complications. Serious spinal fluid leak, which has been 
the most frequent major complication, has been mini-
mal (less than 5%) since reconstructive techniques have 
evolved over the last decade, particularly the local nasal 
septal mucosal flap. Infectious complications are rare 
despite the contamination of the surgical field with nasal 
flora. With the perfection of hemostatic techniques, the 
overall improvement in instrumentation and with the 
development of vascularized flaps for reconstruction 
of dural defects, the benefits of enhanced endoscopic 
visualization and increased access and collaborative 
teamwork certainly have facilitated more effective and 
less morbid effects on the patient. 
Hanna et al [49], had a somewhat different approach 
to cranial base surgery and in their article entitled “Endo-
scopic Resection of Sinonasal Cancers with and without 
Craniotomy” they describe a series of 120 patients, 93 
of whom underwent the endonasal endoscopic approach 
(EEA) and 27 underwent a cranial endoscopic approach 
(CEA) in which the surgical resection involved the addi-
tion of a frontal or subfrontal craniotomy to the transna-
sal endoscopic approach. Approximately two-thirds of the 
patients treated with EEA had a lower disease stage (T1 
to T2) while 95% of the patients treated with CEA had a 
higher disease state (T3, T4). The most common tumor 
types were olfactory neuroblastoma, sarcoma, adenocar-
cinoma , and squamous cell carcinoma. Microscopically 
positive margins were reported in 15% of the patients. 
Out of 120 patients, 15% were treated with surgery alone, 
37% received postoperative radiation therapy, and 13% 
were treated with surgery, radiation therapy, and chemo-
therapy. The overall surgical complication rate was 11% 
for the whole group. The disease control was 85% and 
the five- and 10-year specific disease specific survival 
rates were 87 and 80%, respectively. The authors state 
that endoscopic approaches to the cranial base and si-
nonasal regions offer several advantages, such as: excel-
lent visualization, reduction of the need for craniofacial 
soft tissue dissection, scalp disassembly, and brain 
retraction for tumor access and resection. The authors 
series of 120 patients is the largest series reported in the 
United States to date exclusively dealing with malignant 
tumors treated with endoscopic assisted resection. These 
advantages are the impetus for the increasing adoption 
of endonasal approaches for surgical management of 
sinonasal skull base tumors. 
A previous large series reported from Italy by Nicolai, 
et al [50] recorded 134 patients treated with EEA and 
50 patients treated with CEA. Nicolai’s five-year disease 
specific survival rate was 82%. Endoscopic resection 
of sinonasal cancer should be performed by surgeons 
who have extensive experience in two areas: endoscopic 
technique and surgical oncology. 
SALIVARY GLANDS
There are several studies recently which describe progress 
in the management of tumors of the salivary glands. One 
is a report by Chen and Chang [51] from Taiwan who have 
evaluated the results of minimally invasive endoscopic 
assisted parotidectomy. The authors performed 14 re-
sections of diseased parotid glands using the technique 
of endoscopic parotidectomy. The indications included 
chronic sialadenitis and benign neoplasms carried out 
under general anesthesia through a small incision made 
in the preauricular skin crease. The authors states that 
due to the magnification through the endoscope the 
branches of the facial nerve can be identified easily and 
the tumor could be dissected out and removed through 
the surgical wound. Their complications were minimal 
with only two patients having a transient House Grade II 
facial paresis and in no case was there permanent facial 
paralysis. The harmonic scalpel was used for the cutting 
tissue which also provided hemostasis. It was concluded 
that the advantages of minimally invasive endoscopic as-
sisted parotidectomy included a superior visualization, 
magnification of the key structures and hemostatis and 
the concealment of the scar. 
Douglas et al [52] described gamma knife stereotactic 
radiosurgery for salivary gland neoplasms with invasion 
of the base of the skull following neutron radiotherapy. 
Their aim was to examine the outcome of these patients 
with extensive high grade tumors. Their group of 34 
patients with skull base involvement were treated from 
2001 to 2005 at the University of Washington Cancer 
Center. The authors concluded that patients with pri-
mary salivary gland neoplasms involving the base of 
the skull treated with neutron radiotherapy alone are 
at a high risk of local recurrence. Gamma knife boost 
improved local control and had little additional toxic-
ity. These preliminary results suggest that all patients 
with salivary neoplasms with invasion of the base of the 
skull should be considered for gamma knife boost after 
primary treatment with neutron radiotherapy. 
Dr. Laramore et al [52] at the University of Washing-
ton have been enthusiastic proponents of treatment with 
2WR OD U \QJR ORJ LD3R O VNDWRPQU   O LS LHFV LH US LHñ
$57<.85('$.&<-1<(',725,$/206
primary neutron radiotherapy over more than twenty 
years. In their analysis of the treatment of these tumors, 
they found that the most significant negative prognostic 
factor identified was invasion of the base of the skull. 
Patients not having invasion of the base of the skull had 
a 5 year local control rate of 70% whereas those having 
invasion of the base of the skull had a 5 year local control 
rate of only 19%. The analysis of their treatment planning 
disclosed that areas of the tumors invading above the 
lower portion of the temporal lobes had been relatively 
underdosed with neutron beams leading to this unaccept-
able low local control rate. The authors postulated that 
the additional of a single stereotactic boost using gamma 
knife technology provided an additional dose and as a 
result improved local control. In 2001 they began giving 
the boost to all patients with salivary gland malignan-
cies and invasion of the skull base with a gamma knife 
boost. There was no increase in the complication rate 
accompanying this increase in local control. 
Gopalakrishna Lyer et al [53] from the Sydney Head 
and Neck Cancer of Australia presented their outcomes 
for parotidectomy for metastatic squamous cell carci-
noma with microscopic residual disease and implications 
for facial nerve preservation. The authors had a cohort 
of 15 patients who underwent nerve-sparing surgery 
with involved margins adjacent to the facial nerve were 
treated with adjuvant radiation therapy. A comparison 
of this group to patients with clear margins, showed no 
difference in local recurrence or survival. This study 
suggested that patients with metastatic squamous cell to 
the lymph nodes in the parotid gland with microscopic 
residual disease involving the facial nerve and normal 
function can be successfully treated with a facial nerve-
sparing approach and appropriate doses of postoperative 
adjunctive radiation therapy. 
Loh et al [54] in Toronto reported a study which iden-
tified prognostic factors associated with cancer arising 
in the minor salivary glands. This was a retrospective 
study of 171 patients. The authors found that the 5 year 
and 10 year overall survival in treating minor salivary 
malignancies was 73.8% and 58.1%, respectively. The 
three most common pathological types of minor salivary 
gland malignancies were adenoid cystic mucoepidermoid 
and adenocarcinoma. Multivariant analysis did not show 
any difference in survival between the three groups of pa-
tients. Patients with adenoid cystic carcinoma developed a 
higher degree of local recurrence and distant metastasis 
compared with patients with the other pathological enti-
ties. Grade of disease was a significant variable with high 
grade cancers having a significantly poorer survival. Men 
seemed to have a worse prognosis than women. Tumors 
occurring in the nasal cavity were associated with a poor 
disease free survival and had a greater tendency for local 
recurrence. Although often quoted as a significant factor, 
the stage of disease was not borne out as significant in 
their multivariate analysis. The inability to obtain clear 
margins lead to a higher recurrence rate. In their series, 
50% of those with local recurrence having a positive 
margin required adjuvant therapy. However, despite this 
factor, survival was not different from those with clear 
surgical margins suggesting that adjunctive treatment 
with radiation therapy improves survival up to the same 
levels of patients with clear surgical margins. This was 
especially true in large sinonasal cancers in which com-
plete surgical extirpation may not always be possible. The 
authors concluded that the 5 and 10 year overall disease 
free survival from minor salivary gland cancer is good, 
recurrences are usually local and distant and their data 
indicate that surgery is the main treatment modality either 
alone or in combination with radiation therapy. 
THYROID/PARATHYROID
One of the most remarkable trends in thyroid surgery 
has been to outpatient surgery. Hopkins and Steward 
[55] looked at the issue of outpatient surgery and the 
numerous advances which made it possible. Outpatient 
thyroid surgery is increasingly performed and that the 
length of stay has progressively been shortened from 
several nights to less than 6 hours. This was driven by 
a combination of patient preference and a movement to 
decrease costs. 
However, the risks associated with outpatient thyroid 
surgery must be thoroughly addressed to determine 
Table I. Minimally Invasive Thyroidectomy
Indications Contraindications
Size of thyroid nodule < 4 cm History of thyroids
Thyroid volume of < 30 oc, small to med goiters Large goiters
Thyroid cancer size of < 2 cm Aggressive, high risk, poorly differentiated thyroid cancers, 
i. e., anaplastic, MTC
Low Risk, well differentiated thyroid cancers History of previous head/neck surgery
Follicular neoplasm < 4 cm History of previous neck surgery
Experienced thyroid surgeon Presence of palpable lymphadenopathy
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feasibility. The most common complications of thyroid 
surgery include hypocalcemia, hematoma, injury to the 
recurrent or superior laryngeal nerve, wound infection, 
poor wound healing, pain, and a conspicuous scar. In 
order to decrease the risks, new criteria are being es-
tablished for outpatient thyroid surgery which include: 
nodules smaller than 30 to 50 mm, less than 15 to 20 
milliliters of thyroid volume, no sign of thyroiditis, no 
previous neck surgery or radiation, a non-obese patient, 
cancers less than 2 cm, and no local invasive thyroid 
malignancy. (Table I) [56]. 
 The preoperative predictors of hypocalcemia include 
preoperative vitamin D3 level, calcium levels, intraopera-
tive and immediate parathyroid hormone (PTH) level. 
Postoperative PTH has been shown to be a fast and 
reliable predictor of hypocalcemia. A recent analysis 
confirmed that PTH drawn 1 to 6 hours postoperatively 
can very accurately predict hypocalcemia [57]. 
Other advances in thyroid surgery which have led 
to outpatient surgery include minimally invasive video-
assisted endoscopic assisted thyroid surgery and the use 
of ultrasonic technology such as the harmonic scalpel. 
Nerve monitoring is frequently used in thyroid surgery 
and may be beneficial in the outpatient setting. By us-
ing postoperative PTH testing, technologies (harmonic 
scalpel) to decrease bleeding, low risk patient selection, 
and providing proper patient education the safety of out-
patient thyroid surgery has improved and it has become 
feasible as long as caution is used. 
The surgical approaches currently used may be clas-
sified [58]: 
1. Minimally invasive – mini-incision
2. Encoscopic video assisted
3. Completely closed endoscopic
 • Supraclavicular approach
 • Axillary approach
 • Anterior chest approach
 • Breast approach 
Recurrent laryngeal nerve paralysis is one of the 
most concerning complications after thyroid surgery. 
Reported rates of recurrent laryngeal nerve (RLN) in-
jury range from 1 to 8% and may result in symptoms 
ranging from dysphonia to severe airway compromise. 
Injury may result as a result of stretch, pressure, crush, 
electrocautery, suction trauma, and ischemia, or sev-
ering or excision of a portion of the nerve [59]. Two 
studies involving more than 1.000 and 27.000 nerves 
at risk revealed that visual identification of the nerve 
decreased the rates of permanent RLN palsies when 
compared with cases with no visual identification [60, 
61]. The possibility of predicting vocal cord function 
after thyroidectomy may be important to the surgeon 
before he or she completes a total thyroidectomy if the 
nerve is damaged during the surgery. This may also 
affect the decision for same day discharge as a concern 
about respiratory compromise and to reassure patients 
of voice changes after surgery that these are likely due 
to vocal fold edema or poor effort. 
In a study by Donnellan et al [59] an analysis of the 
Xomed NIM II system was done and the authors data 
suggest that the NIM II may provide information that 
can be important to postoperative vocal cord function. 
However, the authors are quick to point out that “no neu-
romonitoring system can substitute for careful dissection 
and visual nerve identification during thyroid surgery”. 
This becomes extremely important with the findings of 
Cernea et al [62] who analyzed the frequency of extrala-
ryngeal branching of the recurrent laryngeal nerve in a 
consecutive series of patients undergoing thyroidectomy. 
Extralaryngeal branching was found in 64.53% of RLN in 
the series of 1390 RLNs. In patients with intraoperative 
laryngeal nerve monitoring, electrophysiologic activity 
was observed in branches, particularly the anteriorly 
situated ones. Recognition of this frequent anatomical 
configuration and meticulous preservation of all branches 
are of paramount importance to decreased postoperative 
morbidity associated with thyroidectomy. 
Davidson et al [63] used an operating microscope in 
performing thyroid surgery. This allowed the surgeon an 
upright posture while performing thyroid surgery thereby 
reducing the potential for neck and back injury for the 
surgeon while also providing superior magnification of 
the visual field. 
The issue of central compartment dissection in pa-
tients with papillary thyroid carcinoma has become a 
focal point of study in recent years. Zuniga and Sanabria 
[64] in 2009 studied the issue of prophylactic central 
neck dissection in N0 papillary thyroid carcinoma. They 
studied a total of 266 patients with a mean followup time 
of 6.9 years. Five-year neck disease free survival was 
86.8% in patients who underwent central neck dissection 
versus 85.6% in a group that did not undergo central 
neck dissection. Despite the fact that in those patients 
who had the central neck dissection, 112 out of 136 pa-
tients had positive metastatic lymph nodes (82.3%). In 
the multivaried analysis, factors related to central neck 
dissection were macroscopic extrathyroid extension and 
multifocality. They concluded that prophylactic central 
neck dissection did not show an advantage in the rate 
of neck recurrence. 
Ondik, et al [65] studied the opposite position, that is 
the secondary central compartment surgery for thyroid 
cancer. They stated that reoperative thyroid surgery in 
the form of secondary central compartment surgery and/
or lateral neck dissections is increasing. This may be the 
result of two phenomena. The first is the incidence of 
papillary thyroid carcinoma increasing and the second 
is improved diagnostic techniques which are changing 
the management of recurrent thyroid cancer particu-
larly: sensitive thyroglobulin assays, high resolution 
ultrasound techniques, and integrated PET scanning 
which are detecting small recurrent thyroid cancers and 
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prompting surgical intervention in the form of central 
compartment surgery and lateral neck dissections. The 
authors report the feasibility of this surgery, however at 
the cost of a permanent recurrent nerve injury of 6.4%, 
while the transient and permanent hypoparathyroidism 
was 11.9 and 9.5% respectively. This was the case for 
primary central compartment dissection, although as 
mentioned above, this was not shown to alter the outcome. 
Rosenbaum and McHenry [66] studied a series of 110 
patients who underwent initial thyroidectomy. Thera-
peutic central neck dissection was performed in 20% 
of these patients. One patient developed a recurrence in 
the lateral neck. Eighty-eight patients had no abnormal 
lymph nodes and did not undergo central neck dissection. 
Two of these patients subsequently developed a recur-
rence in the central component. Permanent hypoparathy-
roidism occurred in one patient who underwent central 
neck dissection. The authors conclude that after a total 
thyroidectomy and central neck dissection, recurrence 
in the central neck is uncommon, but hypocalcemia 
is more common raising the question about the use of 
routine central neck dissection in patients with papillary 
thyroid carcinoma. 
Similar issues have been raised in patients undergo-
ing minimally invasive parathyroidectomy Smith el al 
[67] reviewed minimally invasive parathryoidectomy in 
patients undergoing initial surgical management of pri-
mary hyperparathyroidism with preoperative localizing 
sestamibi scanning (MIBI) and concordant ultrasonogra-
phy (US) to determine if intraoperative parathyroid hor-
mone is necessary in these patients. Minimally invasive 
parathyroidectomy has become an acceptable therapeutic 
option in treating patients with hyperparathyroidism. 
Preoperative sestamibi scanning, high resolution ul-
trasound wotj Doppler flow and intraoperative PTH 
monitoring have refined this technique. Intraoperative 
PTH monitoring may be eliminated in minimally inva-
sive parathyroid surgery in a carefully selected group 
of patients who have preoperative localizing sestamibi 
scanning (MIBI) with concordant ultrasound as a po-
tentially valid increase in operating room efficiency and 
decrease in cost while performing minimally invasive 
parathyroidectomy.
ROBOTICS
O’Malley and Weinstein in 2007 [68] described the de-
velopment of a novel approach called transoral robotic 
surgery (TORS) using the da Vinci surgical robot which 
provides safe access to the oral cavity, oral pharynx, 
and supraglottis. They also tested their hypothesis that 
robotic surgical technology could be applied to the ante-
rior and midline skull base. The approach also allowed 
excellent visualization and access to the parapharyngeal 
space and to the infratemporal fossa. They developed 
a novel surgical approach called a combined C-TORS 
which enabled them to overcome the instrument angula-
tion and access limitations of TORS. They subsequently 
performed successful surgical dissection of the sphenoid 
sinus, clivus, sella and anterior fossa [68]. 
Weinstein et al [69] applied robotic surgery and the 
TORS technique to cancer of the supraglottis and used a 
canine model to define the parameters of the procedure. 
They felt that the transoral laser supraglottic larynge-
ctomy was superior to the open approach and felt that 
the TORS technique had the potential to be even more 
effective. The authors concluded that the TORS program 
may help to shift the paradigm back to primary surgery 
with or without radiation for the management of cancer 
of the supraglottic larynx.
Weinstein et al [70] quote their experience in 225 
cases performed using the TORS technique at the Uni-
versity of Pennsylvania. They report that this technique 
is feasible since it provides access to almost any lesion in 
the oropharynx as well as many lesions in the supraglot-
tis and hypopharynx. Total operative time paralled the 
exposure time for standard transoral resections. The 
operation was found to be safe and no patient operated 
on using this technique required a blood transfusion. 
Most patients were discharged from the hospital on the 
5th to 7th postoperative day. Minor postoperative com-
plications were encountered. The functional outcome 
was excellent and 96% of their patients were swallowing 
without the use of a gastrostomy tube. The encouraging 
swallowing function afforded by TORS may ultimately 
show an advantage when compared to primary chemo-
radiation for head and neck cancer since in a literature 
review of patients treated with primary chemoradiation 
gastrostomy tube dependence was present in 17 to 30% 
of the patients followed up for one year [71]. 
The authors quote an important paper by Machtay 
[72] that “negative surgical margins always resulted in 
local control” and negative margins were achieved in 
27 patients in their current TORS radical tonsillectomy 
series. They also state that other groups including Moore 
et al [73] and Genden et al [74] all achieved negative 
surgical margins. 
The authors concluded that the financial cost con-
siderations which included the initial cost of approxi-
mately $1.5 million coupled with an approximately 
$100,000 yearly maintenance fee and $200 of dispos-
able instruments per case is a significant financial 
investment, however to date the Intuitive Surgical 
Company which manufactures this instrument has sold 
units in over 1032 academic and community hospital 
sites worldwide [70]. A direct cost analysis comparing 
different treatment modalities is necessary to draw 
further conclusions, but the authors feel that this is 
a cost effective way of treating these cancers. Of note 
is that they also find that teachability, which is a very 
important issue once a new technique is introduced, 
was at a very high level. 
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THYROID ROBOTICS
Kang et al [75] in 2009 reported the operative outcomes 
of 338 consecutive patients undergoing robotic surgery 
of the thyroid using a gasless, transaxillary approach 
with the da Vinci S system. This series was a follow up of 
their initial series of 100 patients with papillary thyroid 
carcinoma all operated on by this technique [76]. All 
patients received prophylactic ipsilateral central compart-
ment neck dissection. Metastasis was identified in 31 
patients. There was one case of transient hypocalcemia 
and two cases of transient hoarseness. Eligibility for 
this surgery included: (1) follicular proliferation with a 
tumor size of less than 5 cm and (2) well-differentiated 
thyroid carcinoma with a tumor size of less than 2 cm 
[75]. Contraindications were: (1) patients with a history 
of previous neck operation; (2) severe Grave’s disease; (3) 
a malignancy with definite extrathryroidal tumor inva-
sion, multiple lateral neck node metastases or perinodal 
infiltration of metastatic lymph nodes or distant metas-
tasis and (4) lesion located in the posterior capsule area 
of the thyroid. Two hundred eighty one patients (84.6%) 
had stage I disease. There were 43 cases of transient 
hypocalcemia, thirteen cases of transient hoarseness, 
three cases of permanent RLN injury. Transient recurrent 
nerve paralysis and hypocalcemia resolved within 2 to 
3 months. The use of this technique results in excellent 
cosmesis, allows for radical central compartment neck 
dissection to be performed and there was no permanent 
hypocalcemia. 
MICROVASCULAR FREE TISSUE  
TRANSFER
Microvascular free flap reconstruction following resection 
of cancer of the head and neck first gained popularity 
in the United States in the 1980s [77]. Since that time 
numerous studies have demonstrated the reliability and 
low morbidity of the use of these flaps in various settings. 
In theory, microvascular reconstruction should contribute 
to improved oncologic outcome since its availability re-
sults in more aggressive oncologic ablation and facilitates 
timely administration of adjuvant therapy. Hanasono et al 
[77] sought to prove this in cancer of the oral cavity and 
reviewed a series of 484 patients who underwent resec-
tion of cancer of the oral cavity at the University of Texas 
MD Anderson Cancer Center over a 25 year period from 
January 1, 1980 to December 31, 2004. The authors state 
that cancers treated after the introduction of free flaps 
included a significantly higher proportion of T4 lesions 
compared to T3 lesions and significantly more advanced 
N stage. Although the cancers were more advanced, sur-
vival and recurrence rates were maintained and the rate 
of positive pathologic margins decreased significantly. 
In addition, fistula and tracheostomy dependence rates 
decreased and rates of intelligible speech increased. 
The authors concluded that reconstructive microsurgery 
contributes to improved oncologic outcomes in addition 
to better function and lower morbidity in the treatment 
of cancer of the oral cavity. 
Chepeha et al [78] described the superior constric-
tor velopharyngoplasty , base of tongue mounding and 
primary hypopharyngeal closure in combination with 
template-based revascularized free tissue transfer in 
the reconstruction of large defects of the palate. After 
this surgery, the patients were able to speak normally 
or required only occasional repetition in speaking in 
public. These results were independent of the size of the 
palate defect. This procedure includes reconstruction 
of the palatal sphincter and resulted in a substantial 
reduction of the size of the native oropharynx. Data on 
swallowing indicated that rehabilitation was not as ef-
fective as with speech. Swallowing results were similar 
to previous techniques which in the larger defects could 
not be optimized with this technique. 
Dirven et al [79] analyzed a series of 144 patients 
treated for T3 and T4 squamous cell carcinoma of the 
larynx and hypopharynx with definitive radiotherapy 
followed by salvage surgery. Radiotherapy dose and 
addition of concurrent chemotherapy proved to be an 
important determinant of pharyngocutaneous fistula. 
It appears that the occurrence of fistula increases with 
concurrent treatment and that reconstruction with highly 
vascularized tissue may decrease both the fistula rate 
and the duration of healing. Even if a tension free pri-
mary closure is achieved in these high risk patients, the 
authors feel that consideration should be given to further 
augment the closure with either regional or free flaps to 
minimize the rate and a duration of the fistula. There 
is an increasing interest in the use of free or regional 
tissue transfer to minimize complications particularly 
in patients who have failed concurrent chemoradiation. 
Nkenke et al [80] studied a series of patients in order 
to determine whether an immediate postoperative period 
of deep sedation, artificial respiration, and monitoring 
in an intensive care unit lead to fewer complications and 
a reduced failure rate of microvascular flaps compared 
with patients who were allowed to breathe spontaneously 
without sedation or admission to the ICU. Their conclu-
sions were that admission to an ICU does not reduce 
complications after microvascular reconstruction and 
therefore should only be considered for selected cases or 
for indications other than monitoring for improvement 
in the circulation of microvascular free flaps.
Hildago et al [81] stated that in the past decade re-
finements in technique for flap inset of existing flaps 
were reported. The author gives us several examples 
such as the mandible reconstruction and emphasizes 
that the basic objectives in reconstruction include: the 
restoration of continuity, widening of intraoral deficits 
and replacement of external skin and soft tissue defects. 
Defects such as these can only be restored effectively 
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with osseocutaneous free tissue transfer, the sources of 
which include the fibula, iliac crest, and scapula. The 
fibula has become the flap of choice for the majority of 
mandibular reconstructions because it provides up to 
30 cm of excellent quality bone that will tolerate multiple 
osteotomies without being devascularized. Good quality 
skin and recipient vessels bind with integrated implants 
for dental restoration and functional results can be out-
standing. In the mid and upper face a variety of flaps 
can provide differing amounts of soft tissue skin surface 
area and bone. Reconstruction includes the external 
skin defect, reconstruction of the palate, restoring the 
oral and nasal passages, and if necessary to cover the 
cranial base. Tissue and bone can be restored. Compared 
to mandibular reconstructions, many of the aesthetic 
results as well as functional results are unsatisfactory. 
These inadequacies, include poor external skin color 
and texture, restoration, that compromises the aesthetic 
results, inadequate reconstruction of functional deficits 
that include loss of sensation and motor function. These 
deficits may be magnified when resection include critical 
midfacial structure such as the lips, muscles of facial 
expression, nose, eyelids and globe. 
Intraoral reconstruction, pharyngoesophageal re-
construction, and laryngeal reconstruction have all been 
greatly enhanced with free tissue transfers. The defects 
of the tongue can be resurfaced and closed with a variety 
of flaps including the radial forearm flap, anterolateral 
thigh flap and rectus abdominus flap. The choice of flap 
depends on the size of the defect and the surface area 
that needs to be covered. The continuity of the cervi-
cal esophagus can also be restored with flaps such as 
the radial forearm flap, lateral thigh flap and jejunum. 
Structures such as the tongue and vocal cords has so 
far defied functional reconstruction.
Cordeiro [82] describes the frontiers of reconstruction 
which are allotransplantation and tissue engineering. 
Allotraplantation, especially composite tissue allografts, 
has been controversial and despite the development of 
immunosuppressive agents over the past four decades 
long term survival is partial. The composite tissue al-
lografts have been more controversial and less developed 
until recently because of the idea that these types of 
tissue transplants are not essential for survival of the 
patient. These consist of varying combinations skin, 
bone, soft tissue, muscles, tendons, and nerves. The ac-
ceptance has been increased by the fact that techniques 
of immunosuppression have become more specific and 
with many fewer side effects. There are multiple centers 
around the world including our own that transplant 
hands and arms and there are now reports of successful 
partial facial transplantation. Technical details follow-
ing transplantation are essentially the same as those 
employed in autotransplantation free flaps. However, the 
applicability of allotransplantation to the head and neck 
particularly for cancer patients ultimately depends not 
upon the technical aspects of the surgery, but the extent 
to which immunosuppression may be developed. The 
ideal immunosuppressive agents will target the tissue 
and organ that is transplanted and allow acceptance of 
the transplanted part without having any other effects on 
the recipient’s tissue. Therefore the ability of the recipient 
to combat residual cancer or any potential metastatic 
sites would remain intact. This form of targeted immu-
nosuppression would have to have no negative effects 
on the outcomes of the cancer. Current limitations of 
applying immunosuppression in the cancer patient can 
be overcome by the development of agents which will 
revolutionize microsurgical reconstruction because it will 
allow transfer of previously unreconstructable specialized 
tissue using well described microsurgical techniques 
which would maximize the aesthetic and functional 
results in head and neck reconstruction. 
Tissue engineering is one of the areas of biotech-
nology that is most rapidly expanding and that could 
potentially have many diverse applications in head and 
neck reconstruction. This consists of completely ex vivo 
engineered three dimensional constructs consisting of 
extracellular matrix in combination with living cells. 
Thus far, constructs of cartilage and bone created from 
stem cells placed into molds, and extracellular matrices 
have allowed creation of three dimensional shapes, such 
as ear frameworks and tracheal cartilage rings. These 
structures have generally not, however, maintained struc-
tural stability. Thus, the problem of transferring these 
types of constructs from the ex vivo site or from a non-
anatomical site technique may still fall into the domain 
of the microsurgeon. Establishing blood supply to these 
constructs remains an unsolved problem.
FOLLOWUP and SURVEILLANCE  
AFTER TREATMENT FOR CANCER  
OF THE HEAD and NECK
There is a widely held observation that the cure rate 
for squamous cell carcinoma of the head and neck has 
not changed appreciably in the last 50 years despite the 
fact that there have been improved types of treatment, 
particularly chemoradiation in an attempt at organ pres-
ervation, selective neck dissections, and microvascular 
reconstruction, all of which have promoted long-term 
disease-free survival but has not improved the cure rate. 
Recurrence is a problem which is present in as much as 
50% of head and neck cancer patients with advanced 
disease and bodes a poor prognosis [83]. The lack of 
improvement in the cure rate is related not only to lack of 
local- regional control but also second primary cancers 
which are often diagnosed in advanced stages in which 
the therapeutic modalities have often been exhausted in 
the treatment of the primary cancer. The static mortality 
rate for these cancers over the years is attributed in part 
to our inability to effectively prevent and treat recur-
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rences and prevent second primary cancers. Even more 
disconcerting are recent studies showing that survival 
for patients with cancer of the larynx has decreased over 
this period [84]. 
Systematic surveillance is advocated to detect asymp-
tomatic recurrent disease since it is assumed that iden-
tification of preclinical disease allows for more affective 
salvage surgery, therefore decreasing cancer specific 
mortality. However, evidence supporting this assumption 
is lacking which helps to perpetuate wide variations in 
surveillance practices. This observation led to a col-
laborative study between the American Head and Neck 
Society and the National Comprehensive Cancer Network 
on advanced consensus surveillance which produced the 
Advanced Consensus Surveillance Guidelines in 2001 
[85]. Despite this publication an optimal surveillance 
strategy has still not evolved. 
Clinicians now question whether scheduled appoint-
ments or surveillance based on the symptoms is the bet-
ter post treatment strategy. Francis et al [83] designed a 
population-based retrospective cohort study to test the 
impact of surveillance intensity on both recurrence and 
survival. This study analyzed a cohort of 3.169 patients 
with cancer of the larynx. The results of this study indi-
cated that approximately 50% of the patients had no visits 
in the nine month preceding their diagnosis of recurrent 
disease, 40% were seen less than recommended, and 
10% were seen equal to or more than recommended. No 
relationship was observed between surveillance intensity 
and one-year survival with the exception of a survival ad-
vantage apparent in patients with recurrent glottic cancer. 
Cancer of the oral cavity and oropharynx is consid-
ered to be a bad prognostic entity in terms of survival 
rate. Failure at the primary site will ultimately occur in 
approximately 20% of these patients. Prospective studies 
have also demonstrated that second primary cancers de-
velop at a rate of 4% to 7% annually in patients who have 
had one primary squamous cell carcinoma in the head 
and neck. Local recurrence and second primary cancers 
are the leading cause of death among patients who have 
undergone treatment for early stage oral cancers [86]. 
Braakhuis et al [87] have proposed a new molecular 
classification for various types of lesions: (1) true second 
primary cancer which is genetically different from the 
original primary; (2) local recurrence in which all mo-
lecular aberrations are similar; (3) second field cancer 
derived from the same genetically altered field as the 
primary tumor, but divergent in later stage; (4) metas-
tasis. Despite its usefulness for categorization, this new 
molecular information is not routinely performed in the 
majority of centers. 
Gonzalez-Garcia et al [88] studied a cohort of 522 
patients with squamous cell carcinoma of the oral cavity 
and oropharynx from 1979 to 2006. Only patients treated 
surgically were considered for evaluation. These patients 
were treated by surgery with or without adjunctive post-
operative radiation therapy. The standard criteria for 
second primary cancers is: (1) the appearance of a new 
tumor of different histological type, (2) tumor of identical 
histological type occurring more than three years after 
treatment of the primary tumor; (3) second primary tu-
mor separated from the initial primary tumor by more 
than 2 cm of clinically normal epithelium. 
There is a considerable risk of second primary can-
cers which remains for years after the original diagnosis. 
The mortality and morbidity from the second primary 
cancer and local recurrence after successful treatment of 
the primary tumor remains one of the most challenging 
problems that we encounter in head and neck surgery. 
The survival rate for patients who had a documented 
second primary cancer was 20 to 32% lower than patients 
diagnosed with oral cavity cancer only. In this study, 
the authors observed that most of the patients were at 
higher risk for the appearance of recurrence during the 
first three years following initial diagnosis. Several fac-
tors have been proposed as determinants for survival in 
patients who have been diagnosed with a local recurrence 
or a second primary cancer; (1) exhaustion of previous 
therapeutic modalities such as maximal dose radiation 
therapy; (2) health impact of previous treatment for the 
primary cancer; (3) overall health status of the patient; 
(4) TNM classification of the second primary cancer or 
local recurrence. Risk factors for the appearance of local 
recurrence included tumor cT3, T4, pT3, T4, advanced 
TNM stages III and IV, surgical margins less than 1 cm, 
bone involvement and administration of post operative 
radiation therapy. These were not factors related to sec-
ond primary cancers. 
Bhattacharyya [89] in reviewing a series of 44.862 
patients with primary cancer of the head and neck ob-
served that a higher incidence of second primary cancers 
was associated with increased age and location of the 
primary cancer in the larynx, hypopharynx, oropharynx, 
nasopharynx, and major salivary glands, but did not 
find any association with respect to the location of the 
primary cancer within the oral cavity. This was similar 
to the findings of Gonzales-Garcia et al [88]. 
The relationship between postoperative radiation 
therapy as a criterion was somewhat controversial and 
the authors [88] were uncertain whether this effect was 
attributable to the more advanced stage of the disease 
of patients who were given adjunctive radiation therapy 
or to DNA damage of adjacent oral epithelium. Surgi-
cal margins of less than 1 cm were predictive for local 
recurrence, but not for second primary cancers. Bone 
involvement was a risk factor for local recurrence, but 
not for second primary cancer. In this series, 34.8% 
of patients with second primary cancers with no local 
recurrence were alive at the end of the followup period 
when isolated second surgery was performed, whereas 
41% died of the disease despite the second surgical 
resection. In contrast, when isolated radiation therapy 
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or chemotherapy was performed, there were no patients 
free of disease at the end of the follow up which certainly 
is a strong indication for primary surgery in these cir-
cumstances. This may be related to more advanced stage 
of the disease in patients treated with combined therapy 
rather than better survival rate with surgery alone. Most 
of the patients had received a maximum radiation dos-
age during the adjuvant treatment following surgical 
resection of the primary tumor which means that this 
may no longer be available to the patient with second 
primary tumor or recurrence. The authors conclude that 
identification of preoperative and postoperative clini-
cal pathological features may predict a higher risk for 
the appearance of local recurrence of second primary 
cancers and should potentially be of interest in deter-
mining which patients could benefit from a closer follow 
up. In a multivariant analysis considering all clinical 
and pathological features, only bone involvement and 
postoperative radiation therapy were accurate predic-
tors for the development of local recurrence. Because 
of the poor survival rate of the affected patients, the 
authors strongly believe that aggressive surgical treat-
ment following the appearance of a second primary or 
local recurrence should be performed, balancing this 
with a potential complication of the second treatment 
modality in head and neck cancer. 
The investigation of the issue of second primary 
tumors was further elaborated on in an article entitled 
“Prediction of Simultaneous Esophageal Lesions in Head 
and Neck Squamous Carcinoma, by Chow et al [90]. As 
a result of exposure to carcinogenic substances such 
as tobacco and alcohol, squamous cell carcinoma of 
the head and neck can coexist with a second primary 
cancer of the aerodigestive tract. The concommittant 
second primary cancers may be located in the head and 
neck, esophagus or lung. To detect the second primary 
cancer, triple endoscopy (laryngoscopy, bronchoscopy, 
and esophagoscopy) is usually performed for patients 
with head and neck squamous cell carcinoma, although 
intensive endoscopic surveillance has not yet been verified 
as being effective [91, 92]. The appearance of a simulta-
neous esophageal cancer, although uncommon, is very 
important because its presence will alter the management 
plan. It is also troublesome if esophageal cancer is found 
during the early follow up period, since the patient may 
require a second surgery which is increasingly difficult 
due to prior surgery and radiation therapy for primary 
in the head and neck. Salvage of the simultaneous lesion 
occurred in 10% of their patients with squamous cell 
carcinoma of the head and neck which is not a manage-
able figure. Esophageal cancer only rarely coexists with 
squamous cell carcinoma of the oral cavity. The authors 
question the role of routine triple endoscopy for all sq-
uamous cell carcinoma and reserve it for patients with 
squamous cell carcinoma of the oropharynx, larynx and 
hypopharynx [90]. 
Imaging studies such as CT, MR, or PET scanning are 
sensitive modalities used to identify lung and esophageal 
cancers. The authors advocate the use of chromol endos-
copy, using Lugol iodine solution, which can be helpful 
in detecting early lesions. The screening for synchronous 
pulmonary cancer, in patients presenting as squamous 
cell carcinoma of the head and neck, is important because 
detection may alter subsequent management. Ghosh et al 
[93] found 60% of the 1882 patients in their cohort had 
clinical and/or radiological evidence of cervical lymph node 
metastasis. Other studies have shown that synchronous 
metastasis are found in 1.5 to 16.8% of patients present-
ing with squamous cell carcinoma of the head and neck. 
The most common site being the lung which accounts for 
68.5% of all synchronous tumors [94, 95]. In addition to 
synchronous distant metastasis, second primary cancers 
have been reported in the lower respiratory tract in 2% of 
patients [96]. As a consequence, screening for synchronous 
second primary cancers in the lung in patients presenting 
with primary or recurrent squamous cell carcinoma of the 
head and neck is important because the presence of such 
cancers is likely to alter the prognosis and therefore the 
detection will alter the subsequent clinical management. 
Ghosh et al [93] state that the overall incidence of 
synchronous pulmonary cancers detected at the time of 
presentation is 3.6%; 1.4% were primary bronchogenic 
carcinoma; and 2.1% were metastasis. In the year fol-
lowing diagnosis, a further 14 patients developed detect-
able pulmonary cancers. They considered that cancers 
detected at the time of the initial screening to be true 
synchronous cancer. The use of dedicated thoracic CT 
scan has proven to be much more sensitive than routine 
chest radiographs in detecting pulmonary cancers, with 
a sensitivity of 90%. The lesions which were missed in 
initial presentation by thoracic CT were predominantly 
pulmonary metastasis. The authors concluded that the 
incidence of synchronous bronchogenic cancers is not 
related to the upper aerodigestive tumor load whereas the 
presence of synchronous pulmonary metastasis appears 
to be related to the presenting tumor load in the head 
and neck. In our Department, we have always considered 
that synchronous second primary cancer in the lung or 
esophagus should be managed first because the results 
often lead to modification of the treatment of cancer of the 
head and neck. Unfortunately screening for lung cancer in 
high risk populations does not confer a survival advantage. 
CONCLUSIONS
Rapid advances in the field of technology and drug de-
velopment have led to improvement of patient care in the 
last decade. Innovations and developments described 
above lead me to believe that in the future we will see 
not only improvement in the quality of but improvement 
in the survival statistics in patients with cancer of the 
head and neck.
2WR OD U \QJR ORJ LD3R O VNDWRPQU   O LS LHFV LH US LHñ
213$57<.85('$.&<-1<(',725,$/
R E F E R E N S
46. Smith R, Klopp C, Williams J. Surgical treatment of cancer 
of the frontal sinus and adjacent areas. Cancer 1954; 7: 991-
94.
 47. Ketcham A, Wilkins R, VanBuren J, Smith R. A combined 
intracranial facial approach to the paranasal sinuses. Am J 
Surg 1963; 106: 698-703.
 48. Snyderman C, Carrau R, Kassam A, Zanation A, Prevedel-
lo D, Gardner P, et al. Endoscopic skull base surgery: Prin-
ciples of endonasal oncologic surgery. J Surg Oncol 2008; 
97(8): 658-64.
 49. Hanna EYN, DeMonte F, Ibrahim S, Roberts D, Levine N, 
Kupferman M. Endoscopic resection of sinonasal cancers 
with and without craniotomy: oncologic results. Arch Otola-
ryngol Head Neck Surg 2009; 135(12): 1219-24.
 50. Nicolai P, Battaglia P, Bignami M, al e. Endoscopic surgery for 
malignant tumors of the sinonasal tract and adjacent skull 
base: a 10-year experience. Am J Rhinol 2008; 22(3): 308-16.
 51. Chen M-K, Chang C-C. Minimally invasive endoscope-assi-
sted parotidectomy: a new approach. Laryngoscope 2007; 
117: 1934-37.
 52. Douglas J, Goodkin R, Laramore G. Gamma knife stereo-
tactic radiosurgery for salivary gland neoplasms with base 
of skull invasion following neutron radiotherapy. Head and 
Neck 2008; 30: 492-96.
 53. Gopalakrishna Lyer N, Clark J, Murali R, Gao K, O'Brien C. 
Outcomes following parotidectomy for metastatic squamous 
cell carcinoma with microscopic residual disease: implica-
tions for facial nerve preservation. Head and Neck 2009; 31: 
21-27.
 54. Loh K, Barker E, Bruch G, O'Sullivan B, Brown D, Goldstein 
D, et al. Prognostic factors in malignancy of the minor sali-
vary glands. Head and Neck 2009; 31: 58-63.
 55. Hopkins B, Steward D. Outpatient thyroid surgery and the 
advances making it possible. Curr Opin Otolaryngol Head 
Neck Surg 2009; 17: 95-99.
 56. Dhiman S, Inabnet W. Minimally invasive surgery for thyroid 
diseases and thyroid cancer. J Surg Oncol 2008; 97: 665-68.
 57. Noordzij J, Lee S, Bernet V, al. E. Early prediction of hy-
pocalcemia after thyroidectomy using parathyroid hormone: 
an analysis of pooled individual patient data from nine ob-
servational studies. J Am Coll Surg 2007; 205: 748-54.
 58. Takami H, Ikeda Y. Total endoscopic thyroidectomy. Asian J 
Surg 2003; 26: 82-85.
 59. Donnellan K, Pitman K, Cannon C, Replogle W, Simmons J. 
Intraoperative laryngeal nerve monitoring during thyroidec-
tomy. Arch Otolaryngol Head and Neck Surg 2009; 135(12): 
1196-98.
 60. Steurer M, Passler C, Denk D, Schneider B, Niederle B, Bi-
genzahn W. Advantages of recurrent laryngeal nerve identi-
fication in thyroidectomy and parathyroidectomy and the 
importance of preoperative and postoperative laryngoscopic 
examination in more than 1000 nerves at risk. Laryngosco-
pe 2002; 112(1): 124-33.
 61. Hermann M, Alk G, Roka R, Glaser K, Freissmuth M. La-
ryngeal recurrent nerve injury in surgery for benign thyroid 
disease: effect of the nerve dissection and impact of indivi-
dual surgeon in more than 27,000 nerves at risk. Ann Surg 
2002; 235(2): 261-68.
 62. Cernea C, Hojaij F, DeCarlucci D, Gotoda R, Plopper C, 
Vanderlei F, et al. Recurrent laryngeal nerve. A plexus rat-
her than a nerve? Arch Otolaryngol Head Neck Surg 2009; 
135(11): 1098-102.
 63. Davidson B, Guardiani E, Wang A. Adopting the operating 
microscope in thyroid surgery: safety, efficiency, and ergono-
mics. Head Neck Surg 2010; 32: 154-59.
 64. Zuniga S, Sanabria A. Prophylactic central neck dissection 
in stage N0 papillary thyroid carcinoma. Arch Otolaryngol 
Head Neck Surg 2009; 135(11): 1087-91.
 65. Ondik M, Dezfoli S, Lipinski L, Ruggiero F, Goldenberg D. 
Secondary central compartment surgery for thyroid cancer. 
Laryngoscope 2009; 119: 1947-50.
 66. Rosenbaum M, McHenry C. Central neck dissection for pa-
pillary thyroid cancer. Arch Otolaryngol Head Neck Surg 
2009; 135(11): 1092-97.
 67. Smith N, Magnuson J, Vidrine D, Kulbersh B, Peters G. Mi-
nimally invasive parathyroidectomy. Use of intraoperative 
parathyroid hormone assays after 2 preoperative localiza-
tion studies. Arch Otolaryngology Head Neck Surg 2009; 
135(11): 1108-11.
 68. O'Malley B, Weinstein G. Robotic skull base surgery. Arch 
Otolaryngol Head Neck Surg 2007; 133(12): 1215-19.
 69. Weinstein G, O'Malley B, Hockstein N. Transoral robotic sur-
gery: supraglottic laryngectomy in a canine model. Laryngo-
scope 2005; 115: 1315-19.
70. Weinstein G, O'Malley B, Desai S, Quon H. Transoral robotic 
surgery: does the ends justify the means? Curr Opin Otola-
ryngol Head Neck Surg 2009; 17(2): 126-31.
 71. Nguyen N, Moltz C, Frank C, al e. Dysphagia following che-
moradiation for locally advanced head and neck cancer. Ann 
Oncol 2004; 15: 383-88.
 72. Machtay M, Perch S, Markiewicz D, al E. Combined surgery 
and post-operative radiotherapy for carcinoma of the base 
of the tongue: analysis of treatment outcome and prognostic 
value of margin status. Head and Neck 1997; 19: 494-99.
 73. Moore E, Olsen KD, Kasperbauer J, al e: Transoral robotic 
surgical extirpation of oropharyngeal neoplasms 7th Inter-
national Conference on Head and Neck Cancer 2004.
 74. Genden E, Desai S, Sung C. Transoral robotic surgery for 
the management of head and neck cancer: a preliminary ex-
perience. Head and Neck 2008; 31: 283-89.
 75. Kang S-W, Lee S, Lee S, Lee K, Jeong J, Lee Y, et al. Robotic 
thyroid surgery using a gasless, transaxillary approach and 
the da Vinci S system: the operative outcomes of 338 conse-
cutive patients. Surgery 2009; 146: 1048-55.
 76. Kang S-W, Jeong J, Yun J-S, Sung T, Lee S, Lee Y, et al. Robot-
-assisted endoscopic surgery for thyroid cancer: experience 
with the first 100 patients. Surg Endosc 2009;Published on-
line March 5 2009(DOI 10.1007/s00464-009-0366-x).
 77. Hanasono M, Friel M, Klem C, Hsu P, Robb G, Weber R, et al. 
Impact of reconstructive microsurgery in patients with advan-
ced oral cavity cancers. Head and Neck 2009; 31(10): 1289-96.
2WR OD U \QJR ORJ LD3R O VNDWRPQU   O LS LHFV LH US LHñ
$57<.85('$.&<-1<(',725,$/214
 78. Chepeha D, Sacco A, Erickson V, Lyden T, Haxer M, Moyer 
J, et al. Oropharyngoplasty with template-based reconstru-
ction of oropharynx defects. Arch Otolaryngol Head Neck 
Surg 2009; 135(9): 887-95.
 79. Dirven R, Swinson B, Gao K, Clark J. The assessment of 
pharyngocutaneous fistula rate in patients treated primari-
ly with definitive radiotherapy followed by salvage surgery 
of the larynx and hypopharynx. Laryngoscope 2009; 119: 
1691-95.
 80. Nkenke E, Vairaktaris E, Stelzie F, Neukam F, St. Pierre M. 
No reduction in complication rate by stay in the Intensive 
Care Unit for patients undergoing surgery for head and neck 
cancer and microvascular reconstruction. Head and Neck 
2009; 31(11): 1461-69.
 81. Hidalgo D, Disa J, Cordeiro P, al. E. A review of 716 conse-
cutive free flaps for oncologic surgical defects: refinement 
in donor-site selection and technique. Discussion: 733-734. 
Plast Reconstr Surg 1998; 103: 722-31.
 82. Cordeiro P. Frontiers in free flap reconstruction in the head 
and neck. J Surg Oncol 2008; 97(8): 669-73.
 83. Francis D, Yueh B, Weymuller E, Merati A. Impact of sur-
veillance on survival after laryngeal cancer in the Medicare 
population. Laryngoscope 2009; 119(12): 2337-44.
 84. Hoffman H, Porter K, Karnell L, al e. Laryngeal cancer in the 
United States: changes in demographics, patterns of care, 
and survival. Laryngoscope 2006; 116: 1-13.
 85. The complete library of NCCN Oncology Practice Guideli-
nes, Version 1. In: Network NCC, ed. Network NCCN Fort 
Washington, PA, 2001.
 86. Mashberg A. Diagnosis of early oral and oropharyngeal squ-
amous carcinoma: obstacles and their amelioration. Oral 
Oncol 2000; 36: 253-55.
 87. Braakhuis B, Tabor M, Leemans C, vander Waal I, Snow 
G, Brakenhoff R. SPTs and field cancerization in oral and 
oropharyngeal cancer: molecular techniques provide new 
insights and definitions. Head and Neck 2002; 24: 198-206.
 88. Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-
Perez J, Rodriguez-Campo F. Local recurrences and second 
primary tumors from squamous cell carcinoma of the oral 
cavity: a retrospective analytic study of 500 patients. Head 
and Neck 2009; 31(9): 1168-80.
 89. Bhattacharyya N. An assessment of risk factors for the de-
velopment of a second primary malignance in the head and 
neck. Ear, Nose, and Throat Journal 2006; 85: 121-25.
 90. Chow TL, Lee D-Y, Choi C-Y, Chan T-F, Lam S-H. Prediction 
of simultaneous esophageal lesions in head and neck squ-
amous cell carcinoma. Arch Otolaryngol Head Neck Surg 
2009; 135(9): 882-85. 
91. Dhooge I, DeVos M, Van Cauwenberge P. Multiple primary 
malignant tumors in patients with head and neck cancer: 
results of a prospective study and future perspectives. La-
ryngoscope 1998; 108(2): 250-56.
 92. Petit T, Georges C, Jung G, al e. Systematic esophageal en-
doscopy screening in patients previously treated for head 
and neck squamous-cell carcinoma. Ann Oncol 2001; 12(5): 
643-46.
 93. Ghosh S, Roland N, Kumar A, Tandon S, Lancaster J, Jack-
son S, et al. Detection of synchronous lung tumors in pa-
tients presenting with squamous cell carcinoma of the head 
and neck. Head and Neck 2009; 31(12): 1563-70.
 94. de Bree R, Deurloo E, Snow G, Leemans C. Screening for 
distant metastases in patients with head and neck cancer. 
Laryngoscope 2000; 110[3 (part 1)] :397-401.
 95. Jackel M, Rausch H. Distant metastasis of squamous epithe-
lial carcinomas of the upper aerodigestive tract. The effect of 
clinical tumor parameters and course of illness. HNO 1999; 
47: 38-44.
 96. Jackel M, Reischl A, Huppert P. Efficacy of radiologic scre-
ening for distant metastases and second primaries in newly 
diagnosed patients with head and neck cancer. Laryngosco-
pe 2007; 117: 242-47.
